The pharmacokinetic evaluation of boceprevir for treatment of Hepatitis C virus

Bibliography

• Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144(10):705–14
   PubMed Web of Science ®Google Scholar
• Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transplant 2003;9(4):331–8
   PubMed Web of Science ®Google Scholar
• Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature 2005;436(7053):933–8
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevention (CDC). Available from: http://www.cdc.gov/hepatitis/hcv/hcvfaq.htm; In:
   Google Scholar
• van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308(24):2584–93
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361(6):580–93
   PubMed Web of Science ®Google Scholar
• Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med 2013;368(20):1907–17
   PubMed Web of Science ®Google Scholar
• US FDA. Victrelis (boceprevir capsules): US prescribing information [online] Available form: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202258lbl.pdf; In:
   Google Scholar
• Australian Public Health Assessment Report for Boceprevir. Australian Government, Department of Health and Ageing. 2012. Review for Boceprevir-8.5.2013.docx. In
   Google Scholar
• Ghosal A, Yuan Y, Tong W, et al. Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor. Drug Metab Dispos 2011;39(3):510–21
   PubMed Web of Science ®Google Scholar
• Venkatraman S, Bogen SL, Arasappan A, et al. Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. J Med Chem 2006;49(20):6074–86
   PubMed Web of Science ®Google Scholar
• Susser S, Welsch C, Wang Y, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology (Baltimore, Md.) 2009;50(6):1709–18
   PubMed Web of Science ®Google Scholar
• Vermehren J, Susser S, Lange CM, et al. Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b. J Viral Hepatitis 2012;19(2):120–7
   PubMed Web of Science ®Google Scholar
• Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010;376(9742):705–16
   PubMed Web of Science ®Google Scholar
• Schiff E, Poordad F, Jacobson I, et al. 104 Boceprevir (B) combination therapy in null responders (nr): response dependent on interferon responsiveness. J Hepatol 2008;48:S46
   Web of Science ®Google Scholar
• Staples CT Jr, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis 1999;29(1):150–4
   PubMed Web of Science ®Google Scholar
• Denis F, Adjide CC, Rogez S, et al. [Seroprevalence of HBV, HCV and HDV hepatitis markers in 500 patients infected with the human immunodeficiency virus]. Pathol Biol 1997;45(9):701–8
   PubMed Web of Science ®Google Scholar
• Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351(5):438–50
   PubMed Web of Science ®Google Scholar
• Laguno M, Cifuentes C, Murillas J, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology (Baltimore, Md.) 2009;49(1):22–31
   PubMed Web of Science ®Google Scholar
• Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001;33(4):562–9
   PubMed Web of Science ®Google Scholar
• Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013;13(7):597–605
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364(13):1195–206
   PubMed Web of Science ®Google Scholar
• Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364(13):1207–17
   PubMed Web of Science ®Google Scholar
• Vierling JM, Helmond FA, Wahl J, et al. 869c. Sustained Virologic Response (SVR) in Prior PegInterferon/ribavirin (PR) treatment failures after retreatment with Boceprevir (BOC) + PR: final results of the PROVIDE study. Gastroenterology 2013;144(5):S–151
   Google Scholar
• Hezode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013;59(3):434–41
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Poordad F, Manns MP, et al. Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. Hepatology (Baltimore, Md.) 2013;57(3):974–84
   PubMed Web of Science ®Google Scholar
• FDA approves Victrelis for Hepatitis C. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm255390.htm [Accessed July 2013]; In:
   Google Scholar
• Mauss S, Hueppe D, Alshuth U. Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. Hepatology (Baltimore, Md.) 2013; Jun 28. doi: 10.1002/hep.26602. [Epub ahead of print]
   Google Scholar
• Burton MJ, Passarella MJ, McGuire BM. Telaprevir and boceprevir in African Americans with genotype 1 chronic hepatitis C: implications for patients and providers. Southern Med J 2012;105(8):431–6
   PubMed Web of Science ®Google Scholar
• Silva MO, Treitel M, Graham DJ, et al. Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3. J Hepatol 2013;59(1):31–7
   PubMed Web of Science ®Google Scholar
• Bruno S, Vierling JM, Esteban R, et al. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. J Hepatol 2013;58(3):479–87
   PubMed Web of Science ®Google Scholar